A Study to Evaluate the Safety and Effectiveness Transdermal Compress Device in Participants with Transfemoral Amputations

Launched by BALMORAL MEDICAL COMPANY · Nov 10, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new device called the Transdermal Compress, which is designed for people who have had a leg amputated above the knee, known as transfemoral amputations. The goal is to see if this device is safe and effective, especially for those who have had trouble using traditional prosthetics. The study is currently looking for participants aged 18 to 65 who are healthy enough to participate and have experienced issues with their current prosthesis or cannot use one at all.

If you or someone you know meets these criteria, participating in the trial will involve providing consent, undergoing evaluations, and following a rehabilitation program for the duration of the study. It's important to note that certain health conditions, such as infections or severe bone issues, might exclude someone from participating. Overall, this trial aims to find better solutions for people with transfemoral amputations, potentially improving their quality of life.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • 1. Participant must be able to understand the investigational nature of this study and has reviewed and provided written, informed consent prior to any study-specific procedures.
• • 2. Participant is a skeletally mature male or female and is 18 - 65 years of age at screening. Participants \< 22 years of age require radiographic confirmation of skeletal maturity and must have failed the use of conventional prosthesis.
• • 3. Participant has an estimated BMI of ≥ 18.5 and ≤ 40 kg/m2 and weight ≤ 245 lbs without prosthesis.
• • 4. Participant has unilateral or bilateral transfemoral limb loss without bone or vascular disease.
• • 5. Participant has problems with conventional prostheses or is not able to use a prosthesis at all or is anticipated to experience problems with a socket prosthesis in the investigator's judgment.
• • 6. Participant has adequate bone stock to support the implanted device
• • 7. Participant does not have any cortical defect located between the expected location of the anchor plug and spindle/bone interface.
• • 8. Participant has the willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full length of the study including the prescribed rehabilitation program.
• • Exclusion Criteria
• • 1. Female participants who are pregnant, nursing, or have a planned pregnancy during the first 12 months post-surgical implantation.
• • 2. Participant had a prior osseointegrated device implanted in the lower limb planned for the study device.
• • 3. Participant has a history of systemic or localized infection at the residual limb site within 6 months prior to Study Day 1.
• • 4. Participant has any distant foci of infections.
• • 5. Participant has a history of sepsis within 6 months prior to Study Day 1.
• • 6. Participant's length of the residual femur cannot accommodate the intramedullary portion of the Transdermal Compress device.
• • 7. Participant has a femoral deformity that in the opinion of the treating surgeon results in an inability to properly insert the Transdermal Compress implant system, and/or results in alignment that is biomechanically unsound.
• • 8. Participant does not have an adequate myofascial flap to allow for circumferential contact with the implanted device.
• • 9. Participant has evidence of or history of severe peripheral vascular disease or insufficiency, muscular atrophy, neuromuscular disease, or diabetes mellitus (Type I or Type II).
• • 10. Participant has evidence of or a documented history of osteomyelitis (excluding the history of osteomyelitis distal to amputation), systemic osteoporosis, or osteomalacia.
• • 11. Participants with identified risk factors for osteoporosis must have a reported T-score \> -2.5 within 6 months prior to Study Day 1.
• • 12. Participant has evidence of or a documented history of severe metabolic disorders that may impair bone formation.
• • 13. Participant has a history of systemically administered corticosteroids or immunosuppressive or immunomodulatory therapy or chemotherapy drugs.
• • 14. Participant has known drug or alcohol dependence currently or within the last year.
• • 15. Participant is a smoker, nicotine, or tobacco user in any form or who has used nicotine or tobacco-containing products within the past 6 months prior to Study Day 1.
• • 16. Participant has any other condition, which in the opinion of the Investigator, precludes the participant's participation in the study or the participant is unlikely to comply with the protocol-defined